Jans Verna, Dondorp Wybo, Mastenbroek Sebastiaan, Mertes Heidi, Pennings Guido, Smeets Hubert, de Wert Guido
Department of Health, Ethics and Society and Research School GROW for Oncology & Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Amsterdam University Medical Center, University of Amsterdam, Center for Reproductive Medicine, Amsterdam Reproduction & Development Research Institute, Amsterdam, Netherlands.
Hum Reprod Open. 2020 Mar 17;2020(2):hoaa003. doi: 10.1093/hropen/hoaa003. eCollection 2020.
The field of reproductive medicine has been criticized for introducing ARTs without systematic research on possible safety risks and for failing to meet the standards of evidence-based innovation held elsewhere in medicine. In this paper, firstly, we ask whether 'responsible innovation' has been a concern for the field, and if so, how it has understood the practical implications of this idea for the development and introduction of potentially risky new ARTs. Secondly, we consider whether the field has indeed fallen short of its responsibilities in this respect, and if so, how things can be improved. To answer these questions, we present three case studies involving the introduction of a new reproductive technology: ICSI, preimplantation genetic testing and mitochondrial replacement therapy. As a framework for analyzing these cases, we used Per Sandin's account of the four dimensions of dealing with risks (threat, uncertainty, action, command) that are central to debates about the possible role of the so-called precautionary principle. We conclude that, although offspring safety concerns have been on the agenda of the debate about bringing the relevant technologies to the clinic, systematic safety and effectiveness studies were not always conducted. As professionals in assisted reproduction have a responsibility to take account of the welfare of the children they are creating, we suggest a policy of proceeding with systematic caution. Legal measures may be needed to ensure that professional guidance is followed in practice. Finally, an open question concerns the threshold for acceptable risk in the context of introducing new ARTs. Multiple stakeholders, including professional societies and patient organizations, should have a role in the urgent debate about this.
生殖医学领域因在未对可能的安全风险进行系统研究的情况下引入辅助生殖技术(ARTs),且未能达到医学其他领域所秉持的循证创新标准而受到批评。在本文中,首先,我们探讨“负责任的创新”是否为该领域所关注,若如此,它如何理解这一理念对潜在有风险的新辅助生殖技术的开发和引入所具有的实际意义。其次,我们思考该领域在这方面是否确实未尽到责任,若如此,如何加以改进。为回答这些问题,我们呈现了三个涉及新生殖技术引入的案例研究:卵胞浆内单精子注射(ICSI)、胚胎植入前基因检测和线粒体替代疗法。作为分析这些案例的框架,我们采用了佩尔·桑丁(Per Sandin)对处理风险的四个维度(威胁、不确定性、行动、指令)的阐述,这些维度是关于所谓预防原则可能作用的辩论的核心。我们得出结论,尽管后代安全问题已被纳入将相关技术引入临床的辩论议程,但并非总是进行系统的安全性和有效性研究。由于辅助生殖领域的专业人员有责任考虑他们所创造孩子的福祉,我们建议采取系统谨慎的政策。可能需要法律措施以确保在实践中遵循专业指导。最后,一个悬而未决的问题涉及在引入新辅助生殖技术的背景下可接受风险的阈值。包括专业协会和患者组织在内的多个利益相关者应参与关于此问题的紧迫辩论。